September 9, 2019 09:25 AM EDTUpdated 10:53 AM

Neurotrope battered in latest Alzheimer's flop; Platelet BioGenesis raises $26M-plus

Kathy Wong

Editor

→ Neurotrope became the latest casualty in the high-risk Alzheimer’s R&D field. The biotech reported that their Phase II study of Bryostatin-1 failed to show …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Neurotrope battered in latest Alzheimer's flop; Platelet BioGenesis raises $26M-plus

Kathy Wong

Editor

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

Sanofi to pay $125M upfront for two immunology drugs from little-known biotech

US drugs rely heavily on ingredients made overseas, new report shows

Exclusive: VelaVigo inks another US biotech deal as China drug development scene booms

Sarepta loses CMO to RNA editing upstart; Another wave of personnel moves at Dyne

Biotech seed rounds sink to lowest level in years as industry slump drags on

New York-based partnership sets the standard for expanding clinical trial access for underserved and diverse ...

Neu­rotrope bat­tered in lat­est Alzheimer's flop; Platelet Bio­Gen­e­sis rais­es $26M-plus

Editor

Sign up to read this article for free.

Gondolabio

Palo Alto, CA, USA

Neurotrope battered in latest Alzheimer's flop; Platelet BioGenesis raises $26M-plus